Virus-Like Particles Made From Human Protein Deliver Cancer-Fighting Peptide Vaccines to Immune Cells | Research

The takeaway

Engineered virus-like particles built from the human PEG10 protein successfully delivered neoantigen peptide vaccines to dendritic cells and triggered strong antitumor responses in mouse liver cancer models.

PEG10-based eVLP
endogenous human protein used to build cancer vaccine delivery particles

What the researchers found

PEG10-based endogenous virus-like particles loaded with neoantigen peptides efficiently targeted dendritic cells, promoted their maturation, and induced neoantigen-specific T cell responses with significant antitumor efficacy in mouse liver cancer models.

Why it matters

Traditional virus-based vaccine delivery faces problems with immune neutralization. Using a human-derived capsid protein sidesteps this issue, potentially enabling more effective and repeatable cancer vaccine administration.

The numbers in context

PEG10 is an endogenous human protein. Neoantigen peptides were genetically encoded into the VLP structure.

How the study worked

Preclinical study engineering PEG10-based VLPs (ePAC) with genetically encoded neoantigens and CpG-ODN surface modification, tested in mouse orthotopic liver cancer and humanized tumor models combined with anti-TIM-3 therapy.

Who was studied

Preclinical cancer vaccine models

What this study cannot tell us

Preclinical mouse data only — no human trials yet; liver cancer focus may not generalize to all tumor types; manufacturing scalability and clinical-grade production not addressed; humanized mouse models only approximate human immune responses.

How to read the evidence

Preliminary preclinical evidence from mouse models. While the approach is innovative, it requires human clinical trials before clinical relevance can be assessed.

When this study was published

Published in 2024 in eLife, representing cutting-edge cancer vaccine platform research.

The bigger picture

This represents a new approach to cancer immunotherapy — using the body's own proteins to build delivery vehicles for personalized cancer vaccines. If it translates to humans, it could overcome the delivery challenges that have limited peptide vaccine effectiveness.

Questions still open

Will the PEG10-based VLP platform avoid immune neutralization in humans as predicted?
Can this platform be adapted for other cancer types beyond liver cancer?
How does ePAC manufacturing complexity and cost compare to existing cancer vaccine approaches?

Common questions

What makes this cancer vaccine delivery system different from others?

It uses PEG10, a protein that naturally exists in human cells, to build virus-like particles. Because these particles are made from a human protein rather than a foreign virus, the immune system is less likely to neutralize them before they deliver their cancer-fighting payload.

How close is this to being used in patients?

It's still in the preclinical (animal testing) stage. While the mouse results are promising — showing strong tumor responses especially when combined with checkpoint immunotherapy — human clinical trials are needed before it could become a treatment option.

Read the original research

Engineering PEG10assembled endogenous virus-like particles with genetically encoded neoantigen peptides for cancer vaccination.

eLife, 13

View on PubMed ↗Publisher’s paper ↗

Citation

Tang, Ruijing; Guo, Luobin; Wei, Tingyu; Chen, Tingting; Yang, Huan; Ye, Honghao; Lin, Fangzhou; Zeng, Yongyi; Yu, Haijun; Cai, Zhixiong; Liu, Xiaolong. (2024). Engineering PEG10assembled endogenous virus-like particles with genetically encoded neoantigen peptides for cancer vaccination.. eLife, 13. https://doi.org/10.7554/eLife.98579